Italian P&R Group acquires Biofarmitalia and strengthens its leadership in pharmaceutical innovation

The acquired company is a leader in the field of delivery systems and medical devices

Effective October 7th, the P&R SpA Group has completed the acquisition of the Italian based Biofarmitalia.

With its 20-year know-how, Biofarmitalia is a leader in the research and manufacture of transcutaneous patches, impregnated matrices and medical devices for the delivery of active principles by dermal and oral route.

With this acquisition, P&R Group consolidates its leadership in the field of pharmaceuticals and innovative delivery systems, in terms of market share and at R&D level.


Find out more about Fidia’s product portfolio:

Go to the website

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine